{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T11:09:15Z","timestamp":1785150555388,"version":"3.55.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,25]],"date-time":"2021-10-25T00:00:00Z","timestamp":1635120000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,25]],"date-time":"2021-10-25T00:00:00Z","timestamp":1635120000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100013995","name":"Sanofi Genzyme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013995","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Acid sphingomyelinase deficiency (ASMD), historically known as Niemann\u2013Pick disease (NPD) types A, A\/B, and B, is a rare, progressive, potentially fatal lysosomal storage disease with a spectrum of phenotypes. Little is known about how ASMD symptoms affect the lives of patients and their caregivers. In a cross-sectional qualitative study conducted in the US and UK, and in collaboration with the National Niemann\u2013Pick Disease Foundation (US) and Niemann\u2013Pick UK, we investigated the symptom experience of patients with ASMD types B and A\/B and explored how the disease impacts their and their caregivers\u2019 lives. The study included 17 adult patients (mean age 38.7\u00a0years, 12 female), three caregivers of adults with ASMD, 12 pediatric\/adolescent patients with ASMD (mean age 10.5\u00a0years, six female), and 12 caregivers of pediatric\/adolescent patients with ASMD. The most commonly reported disease manifestations were respiratory (n\u2009=\u200926, 89.7%), abdominal (n\u2009=\u200925, 86.2%), and musculoskeletal symptoms (n\u2009=\u200923, 79.3%); excessive bleeding or bruising (n\u2009=\u200920, 69%); fatigue (n\u2009=\u200920, 69%); gastrointestinal symptoms (n\u2009=\u200918, 62.1%); and headache (n\u2009=\u200915, 51.7%). ASMD was reported to negatively impact patients\u2019 physical function (n\u2009=\u200923, 79.3%), self-esteem (n\u2009=\u200918, 62.1%), emotions (n\u2009=\u200916, 55.2%), social function and relationships (n\u2009=\u200916, 55.2%), and personal care (n\u2009=\u20099, 31%). Providing care for individuals with ASMD negatively affected caregivers\u2019 emotional well-being (n\u2009=\u200912, 80%), social function (n\u2009=\u20094, 26.7%), relationships (n\u2009=\u20096, 40%), and financial security (n\u2009=\u20097, 46.7%). The physical toll of providing care, the need for lifestyle changes, and the responsibility for making medical decisions added to the burden for caregivers. Alternatively, some caregivers noted that caring for a loved one enhanced their spirituality, providing them with a different outlook on life and a deeper personal resolve. This study showed that ASMD is a substantial burden for patients and caregivers, with long-term physical, emotional, social, and financial impacts. The study confirmed commonly known manifestations of ASMD, especially respiratory problems, but also identified less recognized ones, such as dermatological complications. The data collected and insight gained from this study should enhance clinical care, help evaluate new treatments, and inform health care decision making for patients with ASMD.<\/jats:p>","DOI":"10.1038\/s41598-021-99921-6","type":"journal-article","created":{"date-parts":[[2021,10,25]],"date-time":"2021-10-25T10:02:36Z","timestamp":1635156156000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Impact and burden of acid sphingomyelinase deficiency from a patient and caregiver perspective"],"prefix":"10.1038","volume":"11","author":[{"given":"Robin","family":"Pokrzywinski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asha","family":"Hareendran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luba","family":"Nalysnyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandy","family":"Cowie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joslyn","family":"Crowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Hopkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhaivat","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Pulikottil-Jacob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,25]]},"reference":[{"issue":"6","key":"99921_CR1","doi-asserted-by":"publisher","first-page":"e672","DOI":"10.1542\/peds.2004-0887","volume":"114","author":"MP Wasserstein","year":"2004","unstructured":"Wasserstein, M. P. et al. The natural history of type B Niemann\u2013Pick disease: Results from a 10-year longitudinal study. Pediatrics 114(6), e672\u2013e677 (2004).","journal-title":"Pediatrics"},{"issue":"2","key":"99921_CR2","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.beem.2014.08.004","volume":"29","author":"SD Kingma","year":"2015","unstructured":"Kingma, S. D., Bodamer, O. A. & Wijburg, F. A. Epidemiology and diagnosis of lysosomal storage disorders; Challenges of screening. Best Pract. Res. Clin. Endocrinol. Metab. 29(2), 145\u2013157 (2015).","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"issue":"1","key":"99921_CR3","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s13023-017-0572-x","volume":"12","author":"MM McGovern","year":"2017","unstructured":"McGovern, M. M., Avetisyan, R., Sanson, B. J. & Lidove, O. Disease manifestations and burden of illness in patients with acid sphingomyelinase deficiency (ASMD). Orphanet. J. Rare Dis. 12(1), 41 (2017).","journal-title":"Orphanet. J. Rare Dis."},{"issue":"5","key":"99921_CR4","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1007\/s10545-007-0632-9","volume":"30","author":"EH Schuchman","year":"2007","unstructured":"Schuchman, E. H. The pathogenesis and treatment of acid sphingomyelinase-deficient Niemann\u2013Pick disease. J. Inherit. Metab. Dis. 30(5), 654\u2013663 (2007).","journal-title":"J. Inherit. Metab. Dis."},{"issue":"2","key":"99921_CR5","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.beem.2014.10.002","volume":"29","author":"EH Schuchman","year":"2015","unstructured":"Schuchman, E. H. & Wasserstein, M. P. Types A and B Niemann\u2013Pick disease. Best Pract. Res. Clin. Endocrinol. Metab. 29(2), 237\u2013247 (2015).","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"issue":"12","key":"99921_CR6","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1002\/ppul.20725","volume":"42","author":"N Guillemot","year":"2007","unstructured":"Guillemot, N., Troadec, C., de Villemeur, T. B., Clement, A. & Fauroux, B. Lung disease in Niemann\u2013Pick disease. Pediatr. Pulmonol. 42(12), 1207\u20131214 (2007).","journal-title":"Pediatr. Pulmonol."},{"issue":"3","key":"99921_CR7","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.ymgme.2012.06.015","volume":"107","author":"CE Hollak","year":"2012","unstructured":"Hollak, C. E. et al. Acid sphingomyelinase (Asm) deficiency patients in The Netherlands and Belgium: Disease spectrum and natural course in attenuated patients. Mol. Genet. Metab. 107(3), 526\u2013533 (2012).","journal-title":"Mol. Genet. Metab."},{"key":"99921_CR8","doi-asserted-by":"crossref","unstructured":"McGovern, M. M. et al. A prospective, cross-sectional survey study of the natural history of Niemann\u2013Pick disease type B. Pediatrics 122(2), e341\u2013e349 (2008).","DOI":"10.1542\/peds.2007-3016"},{"key":"99921_CR9","unstructured":"Wasserstein, M. P. & Schuchman, E. H. Acid sphingomyelinase deficiency. in GeneReviews\u00ae [Internet] (eds Adam, M. P. et al.). (University of Washington, 1993)."},{"issue":"8","key":"99921_CR10","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1038\/gim.2013.4","volume":"15","author":"MM McGovern","year":"2013","unstructured":"McGovern, M. M. et al. Morbidity and mortality in type B Niemann\u2013Pick disease. Genet. Med. 15(8), 618\u2013623 (2013).","journal-title":"Genet. Med."},{"issue":"11","key":"99921_CR11","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1002\/ajmg.a.33077","volume":"149A","author":"SL Henderson","year":"2009","unstructured":"Henderson, S. L., Packman, W. & Packman, S. Psychosocial aspects of patients with Niemann\u2013Pick disease, type B. Am. J. Med. Genet. A 149A(11), 2430\u20132436 (2009).","journal-title":"Am. J. Med. Genet. A"},{"issue":"6","key":"99921_CR12","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1093\/intqhc\/mzm042","volume":"19","author":"A Tong","year":"2007","unstructured":"Tong, A., Sainsbury, P. & Craig, J. Consolidated criteria for reporting qualitative research (COREQ): A 32-item checklist for interviews and focus groups. Int. J. Qual. Health Care 19(6), 349\u2013357 (2007).","journal-title":"Int. J. Qual. Health Care"},{"key":"99921_CR13","doi-asserted-by":"crossref","unstructured":"Faulkner, S. L. & Trotter, S. P. Data saturation. in The International Encyclopedia of Communication Research Methods. (eds Matthes, J. et al.) 1\u20132 (Wiley, 2017).","DOI":"10.1002\/9781118901731.iecrm0060"},{"issue":"5","key":"99921_CR14","doi-asserted-by":"publisher","first-page":"363","DOI":"10.2165\/00019053-200826050-00002","volume":"26","author":"NK Leidy","year":"2008","unstructured":"Leidy, N. K. & Vernon, M. Perspectives on patient-reported outcomes: Content validity and qualitative research in a changing clinical trial environment. Pharmacoeconomics 26(5), 363\u2013370 (2008).","journal-title":"Pharmacoeconomics"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-99921-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-99921-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-99921-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T16:42:16Z","timestamp":1670085736000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-99921-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,25]]},"references-count":14,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["99921"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-99921-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,25]]},"assertion":[{"value":"16 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"RP and AH are employees of Evidera, which was paid by Sanofi Genzyme for work related to this study. DJ and RPJ are current employees of Sanofi Genzyme and may hold shares and\/or stock options in the company. LN was employed by Sanofi Genzyme while the study was conducted and may hold shares and\/or stock options in the company. SC, JC, and JH declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20972"}}